HCG Injection for Male and Female Fertility
For males with hypogonadotropic hypogonadism seeking fertility, hCG injections (1500-2500 IU, 2-3 times weekly) are the first-line treatment to induce spermatogenesis, with FSH added after 2-4 months if testosterone normalizes but sperm production remains inadequate. For females undergoing ovulation induction with gonadotropins, a single dose of 5,000-10,000 IU hCG triggers final oocyte maturation when follicles reach 18mm diameter.
Male Fertility Treatment
Hypogonadotropic Hypogonadism (Primary Indication)
hCG is the only medical treatment that can restore both testosterone production and spermatogenesis in men with pathologic gonadotropin deficiency 1, 2. This represents the sole medically treatable cause of male infertility.
Dosing Protocol for Males:
- Initial therapy: hCG 1500-2500 IU intramuscularly 2-3 times weekly 1, 2, 3
- FDA-approved regimens 4:
- 500-1000 IU three times weekly for 3 weeks, followed by same dose twice weekly for 3 weeks
- 4000 IU three times weekly for 6-9 months, then reduced to 2000 IU three times weekly for additional 3 months
Treatment Strategy:
Recent evidence strongly supports starting with FSH monotherapy for 2-4 months BEFORE adding hCG 1. This approach:
- Improves subsequent fertility outcomes
- Shortens overall treatment duration to achieve spermatogenesis
- Optimizes testicular response
After FSH priming, add hCG to normalize testosterone levels. If sperm production remains inadequate after testosterone normalization, continue combined hCG + FSH therapy 3, 5.
Expected Outcomes:
- 78% of men achieve any sperm output within median 5 months 5
- 56% reach >2 million sperm/mL within median 12 months 5
- 49% reach >5 million sperm/mL within median 14 months 5
- Treatment leads to testicular growth, progressive androgenization, and ultimately spermatogenesis 1
Critical caveat: The major determinant of pregnancy success is female partner fertility status, not male sperm parameters. Men with female partners having adverse fertility factors require median 43 months to pregnancy versus 15 months without female factors 5.
Monitoring Parameters for Males:
- Testosterone levels: Should normalize before expecting spermatogenesis
- Semen analysis: Every 3 months during treatment
- Testicular volume: Should increase significantly (mean increase from 3.08 to 8.92 mL) 6
- Secondary sexual characteristics: Beard, pubic/axillary hair development 6
- Physical strength and well-being 6
Contraindications and Warnings:
Never prescribe exogenous testosterone to men desiring fertility 2. Testosterone provides negative feedback to the hypothalamus/pituitary, suppressing gonadotropins and halting spermatogenesis. Recovery after cessation may take months to years, or rarely may not occur 2.
Other Male Infertility Contexts:
For non-obstructive azoospermia with normal gonadotropins, hCG use is off-label with limited supporting evidence 2. For idiopathic oligospermia, evidence remains conflicting and insufficient to recommend routine use 3, 7.
One study showed hCG combined with clomiphene citrate (25mg daily) achieved 47.4% sperm appearance rate at 12 months, though sperm quality remained poor 8. However, this combination lacks robust evidence and is not standard practice.
Female Fertility Treatment
Ovulation Induction (Primary Indication)
For women undergoing controlled ovarian stimulation with gonadotropins (menotropins/FSH), administer 5,000-10,000 IU hCG as a single injection when lead follicle reaches 18mm mean diameter 4, 9.
Dosing for Females:
- Standard dose: 5,000-10,000 IU intramuscularly as single injection 4
- Recombinant hCG: 250 mcg subcutaneously (equivalent to 5,000-10,000 IU urinary hCG) 10
- Timing: One day following last dose of menotropins 4
Trigger Criteria:
The 2025 ESHRE guideline specifies hCG administration when 9:
- Lead follicle diameter ≥18mm
- Serum estradiol >200 pg/mL (0.73 nmol/L)
- For natural cycles: Give when follicle reaches 18-24mm with E2 >200 pg/mL 11
To prevent multiple pregnancy and OHSS, withhold hCG when 12:
- More than 2 dominant follicles >15mm, OR
- More than 5 follicles >10mm
Recombinant vs Urinary hCG:
250 mcg recombinant hCG produces equivalent outcomes to 5,000-10,000 IU urinary hCG with significantly fewer injection site reactions 10. The 500 mcg dose increases OHSS risk without improving pregnancy rates 10.
Luteal Phase Support:
Adding hCG for luteal support in natural cycles does NOT improve pregnancy rates 13. Standard luteal support with progesterone alone is sufficient. The single study showing hCG increased mid-luteal estradiol found no corresponding pregnancy rate improvement 13.
IVF Context:
Intrauterine hCG administration before embryo transfer should NOT be offered as an IVF add-on 14. A 2026 IPD meta-analysis of 2,244 participants from trustworthy RCTs showed no improvement in live birth (OR 0.99,95% CI 0.83-1.19) or clinical pregnancy rates (OR 1.04,95% CI 0.83-1.31) 14. Studies claiming benefit failed trustworthiness criteria.
Monitoring and Safety
For Both Sexes:
- Reconstituted hCG must be used within 60 days and refrigerated 4
- Monitor for OHSS in females (dose-dependent risk)
- Assess for local injection site reactions (less common with recombinant formulations)
Female-Specific Monitoring:
- Follicle size and number via ultrasound
- Serum estradiol levels
- Signs/symptoms of OHSS
- Cancel cycle if excessive follicular response
Male-Specific Monitoring:
- Baseline and follow-up (1-3 months, then 6-12 months): Digital rectal exam, PSA, hematocrit 15
- Contraindications: Prostate cancer, breast cancer 15
- Relative contraindications: Sleep apnea, peripheral edema, erythrocytosis (hematocrit >52%), benign prostatic hyperplasia 15
Key Clinical Pitfalls
Starting testosterone instead of hCG in hypogonadal men desiring fertility - This is the most common and devastating error, potentially causing irreversible infertility 2
Not priming with FSH before hCG in hypogonadotropic hypogonadism - Recent evidence shows 2-4 months FSH monotherapy first improves outcomes 1
Using hCG for luteal support or intrauterine administration in IVF - No benefit demonstrated, wastes resources 13, 14
Inadequate female partner evaluation in male factor cases - Female fertility factors are the primary determinant of pregnancy success, not male sperm parameters 5
Triggering ovulation with excessive follicular development - Increases multiple pregnancy and OHSS risk; cancel cycle if >2 follicles >15mm or >5 follicles >10mm 12